Literature DB >> 10751800

Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin at Patient's Home.

.   

Abstract

We have applied the low molecular weight heparin dalteparin as once-daily subcutaneous injections to the treatment of deep vein thrombosis (DVT) on an outpatient basis since 1994. Until today, 377 consecutive patients with DVT below the inguinal ligament have been treated at home with dalteparin. The patients administered the injections themselves or with the help of either a relative or a primary nurse. Here we report the outcome of the 212 patients treated during 1994-1995, which has been followed for 2 years after the start of treatment. At the 2-year follow-up only 13 patients (6.6%) had suffered a recurrent DVT and of these none were on continuous dicumarol treatment. No cases of major bleedings were seen. This new therapeutic approach for the treatment of DVT is safe, most of the patients are able to treat themselves, and the patients are satisfied with the home treatment model.

Entities:  

Year:  1998        PMID: 10751800     DOI: 10.1023/A:1008866025015

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  15 in total

1.  Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group.

Authors:  P Lindmarker; M Holmström
Journal:  J Intern Med       Date:  1996-12       Impact factor: 8.989

2.  A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.

Authors:  S Schulman; A S Rhedin; P Lindmarker; A Carlsson; G Lärfars; P Nicol; E Loogna; E Svensson; B Ljungberg; H Walter
Journal:  N Engl J Med       Date:  1995-06-22       Impact factor: 91.245

3.  The long-term clinical course of acute deep venous thrombosis.

Authors:  P Prandoni; A W Lensing; A Cogo; S Cuppini; S Villalta; M Carta; A M Cattelan; P Polistena; E Bernardi; M H Prins
Journal:  Ann Intern Med       Date:  1996-07-01       Impact factor: 25.391

4.  Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg.

Authors:  M Holmoström; M C Berglund; S Granquist; G Bratt; E Törnebohm; D Lockner
Journal:  Thromb Res       Date:  1992-07-01       Impact factor: 3.944

5.  Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis.

Authors:  A Leizorovicz; G Simonneau; H Decousus; J P Boissel
Journal:  BMJ       Date:  1994-07-30

6.  A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.

Authors:  M Levine; M Gent; J Hirsh; J Leclerc; D Anderson; J Weitz; J Ginsberg; A G Turpie; C Demers; M Kovacs
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 91.245

7.  Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.

Authors:  M M Koopman; P Prandoni; F Piovella; P A Ockelford; D P Brandjes; J van der Meer; A S Gallus; G Simonneau; C H Chesterman; M H Prins
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 91.245

8.  Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis.

Authors:  P Lindmarker; M Holmström; S Granqvist; H Johnsson; D Lockner
Journal:  Thromb Haemost       Date:  1994-08       Impact factor: 5.249

9.  A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis.

Authors:  G Bratt; E Törnebohm; S Granqvist; W Aberg; D Lockner
Journal:  Thromb Haemost       Date:  1985-12-17       Impact factor: 5.249

10.  Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT).

Authors:  G Bratt; W Aberg; M Johansson; E Törnebohm; S Granqvist; D Lockner
Journal:  Thromb Haemost       Date:  1990-12-28       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.